Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for autoimmune diseases and cancers. Its lead candidate, AlloNK, is a non-genetically modified, cryopreserved therapy designed to work with monoclonal antibodies to deplete B… From the company’s description.
In fiscal 2025, Artiva Biotherapeutics, Inc. reported a net loss of $83.86M. Operations used $76.75M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Artiva Biotherapeutics, Inc. does
In the company’s own words
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for autoimmune diseases and cancers. Its lead candidate, AlloNK, is a non-genetically modified, cryopreserved therapy designed to work with monoclonal antibodies to deplete B cells; it is being evaluated in clinical trials for conditions including rheumatoid arthritis, Sjögren’s disease, systemic sclerosis, lupus and idiopathic inflammatory myopathies. Artiva also holds rights outside Asia-Pacific to AB-201, a HER2-targeting CAR-NK candidate, and AB-205, a CD5-targeting CAR-NK candidate. The company has a proprietary manufacturing platform and operates a 9,000-square-foot, current Good Manufacturing Practices-compliant cell production facility in San Diego. Founded in 2019 as a spinout of South Korea’s GC Cell, Artiva received exclusive worldwide rights outside Asia-Pacific to GC Cell’s NK cell manufacturing technology and programs. Its pipeline also includes programs advanced through collaborator-funded trials.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1817241
- SIC
- 2836
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Artiva Biotherapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Artiva Biotherapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Artiva Biotherapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Artiva Biotherapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Artiva Biotherapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”